Pliant Therapeutics: Funding, Investors & Team (Oct 2026)
Malleable Therapeutics is a clinical stage biopharmaceutical organization zeroed in on finding and creating novel treatments for the treatment of fibrosis. Flexible's lead item competitor, PLN-74809, is an oral little atom double particular inhibitor of avß6 and avß1 integrins that it is producing for the treatment of idiopathic aspiratory fibrosis, or IPF, and essential sclerosing cholangitis, or PSC. PLN-74809 has gotten Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Flexible is as of now selecting two Phase 2a preliminaries of PLN-74809 for the treatment of IPF and plans to start a Phase 2a preliminary in PSC in the last part of 2020. Flexible's second item up-and-comer, PLN-1474, is a little particle specific inhibitor of avß1 for the treatment of liver fibrosis related with nonalcoholic steatohepatitis, or NASH, which Pliant has banded together with Novartis. PLN-1474 is right now going through a Phase 1 preliminary. Notwithstanding clinical stage programs, Pliant right now has two preclinical projects focusing on oncology and solid dystrophies.
Pliant Therapeutics has raised $450M across 2 funding rounds on record, the most recent an undisclosed round of $250M announced in Jan 2023.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Pliant Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Pliant Therapeutics Funding Rounds
Pliant Therapeutics raised $200M in a Post-IPO Equity announced in Jul 2022.
6 months later, an undisclosed round of $250M was announced in Jan 2023.
Pliant Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Pliant Therapeutics Funding Compared to Other Biotechnology Startups
Pliant Therapeutics' latest round of $250M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Pliant Therapeutics in Biotechnology and South San Francisco
Companies Similar to Pliant Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Pliant Therapeutics Funding FAQs
What does Pliant Therapeutics do?
Malleable Therapeutics is a clinical stage biopharmaceutical organization zeroed in on finding and creating novel treatments for the treatment of fibrosis. Flexible's lead item competitor, PLN-74809, is an oral little atom double particular inhibitor of avß6 and avß1 integrins that it is producing for the treatment of idiopathic aspiratory fibrosis, or IPF, and essential sclerosing cholangitis, or PSC. PLN-74809 has gotten Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Flexible is as of now selecting two Phase 2a preliminaries of PLN-74809 for the treatment of IPF and plans to start a Phase 2a preliminary in PSC in the last part of 2020. Flexible's second item up-and-comer, PLN-1474, is a little particle specific inhibitor of avß1 for the treatment of liver fibrosis related with nonalcoholic steatohepatitis, or NASH, which Pliant has banded together with Novartis. PLN-1474 is right now going through a Phase 1 preliminary. Notwithstanding clinical stage programs, Pliant right now has two preclinical projects focusing on oncology and solid dystrophies.
How much funding has Pliant Therapeutics raised?
Pliant Therapeutics has raised $450M across 2 rounds on record. The most recent is an undisclosed round of $250M announced in Jan 2023.
When did Pliant Therapeutics last raise funding?
Pliant Therapeutics' most recent funding round on record is an undisclosed round of $250M, announced in Jan 2023.
Who founded Pliant Therapeutics?
FundedIQ lists Bill Degrado (Founder), Hal Chapman (Founder) at Pliant Therapeutics.
Where is Pliant Therapeutics headquartered?
Pliant Therapeutics is based in South San Francisco, California, United States.
How many employees does Pliant Therapeutics have?
Pliant Therapeutics is in the 101-250 employee band.
How does Pliant Therapeutics' funding compare to other Biotechnology startups?
Pliant Therapeutics' latest round of $250M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Pliant Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Pliant Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.